Literature DB >> 27341604

Value in Colorectal Cancer Treatment: Where It Is Lacking, and Why.

Leonard B Saltz1.   

Abstract

Treatment options have improved for patients with colorectal cancer, but these improvements have invariably been more modest than had been anticipated or hoped for. Yet while outcomes have improved modestly, costs have risen substantially, as prices of the newer anticancer agents in colorectal cancer have led the way in the stratospheric rise in cancer drug prices in general. Development of future strategies that will be both sustainable and attainable by all who need them will require both an understanding of past events that have brought us to the present and a willingness to confront the limitations of our present options and to assess them for the true value that they do or do not offer.

Entities:  

Mesh:

Year:  2016        PMID: 27341604      PMCID: PMC5543411          DOI: 10.1097/PPO.0000000000000194

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  18 in total

1.  Perspectives on Cost and Value in Cancer Care.

Authors:  Leonard B Saltz
Journal:  JAMA Oncol       Date:  2016-01       Impact factor: 31.777

2.  Considering Efficacy and Cost, Where Does Ramucirumab Fit in the Management of Metastatic Colorectal Cancer?

Authors:  Daniel A Goldstein; Bassel F El-Rayes
Journal:  Oncologist       Date:  2015-08-11

3.  The Value of Considering Cost, and the Cost of Not Considering Value.

Authors:  Leonard B Saltz
Journal:  J Clin Oncol       Date:  2015-12-14       Impact factor: 44.544

4.  Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.

Authors:  Josep Tabernero; Takayuki Yoshino; Allen Lee Cohn; Radka Obermannova; Gyorgy Bodoky; Rocio Garcia-Carbonero; Tudor-Eliade Ciuleanu; David C Portnoy; Eric Van Cutsem; Axel Grothey; Jana Prausová; Pilar Garcia-Alfonso; Kentaro Yamazaki; Philip R Clingan; Sara Lonardi; Tae Won Kim; Lorinda Simms; Shao-Chun Chang; Federico Nasroulah
Journal:  Lancet Oncol       Date:  2015-04-12       Impact factor: 41.316

5.  Randomized trial of TAS-102 for refractory metastatic colorectal cancer.

Authors:  Robert J Mayer; Eric Van Cutsem; Alfredo Falcone; Takayuki Yoshino; Rocio Garcia-Carbonero; Nobuyuki Mizunuma; Kentaro Yamazaki; Yasuhiro Shimada; Josep Tabernero; Yoshito Komatsu; Alberto Sobrero; Eveline Boucher; Marc Peeters; Ben Tran; Heinz-Josef Lenz; Alberto Zaniboni; Howard Hochster; James M Cleary; Hans Prenen; Fabio Benedetti; Hirokazu Mizuguchi; Lukas Makris; Masanobu Ito; Atsushi Ohtsu
Journal:  N Engl J Med       Date:  2015-05-14       Impact factor: 91.245

6.  Colorectal Cancer Survival Gains and Novel Treatment Regimens: A Systematic Review and Analysis.

Authors:  Irfan Jawed; Julia Wilkerson; Vinay Prasad; Austin G Duffy; Tito Fojo
Journal:  JAMA Oncol       Date:  2015-09       Impact factor: 31.777

7.  Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.

Authors:  Jaafar Bennouna; Javier Sastre; Dirk Arnold; Pia Österlund; Richard Greil; Eric Van Cutsem; Roger von Moos; Jose Maria Viéitez; Olivier Bouché; Christophe Borg; Claus-Christoph Steffens; Vicente Alonso-Orduña; Christoph Schlichting; Irmarie Reyes-Rivera; Belguendouz Bendahmane; Thierry André; Stefan Kubicka
Journal:  Lancet Oncol       Date:  2012-11-16       Impact factor: 41.316

8.  First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis.

Authors:  Daniel A Goldstein; Qiushi Chen; Turgay Ayer; David H Howard; Joseph Lipscomb; Bassel F El-Rayes; Christopher R Flowers
Journal:  J Clin Oncol       Date:  2015-02-17       Impact factor: 44.544

9.  Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer.

Authors:  Daniel A Goldstein; Bilal B Ahmad; Qiushi Chen; Turgay Ayer; David H Howard; Joseph Lipscomb; Bassel F El-Rayes; Christopher R Flowers
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

10.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Authors:  Axel Grothey; Eric Van Cutsem; Alberto Sobrero; Salvatore Siena; Alfredo Falcone; Marc Ychou; Yves Humblet; Olivier Bouché; Laurent Mineur; Carlo Barone; Antoine Adenis; Josep Tabernero; Takayuki Yoshino; Heinz-Josef Lenz; Richard M Goldberg; Daniel J Sargent; Frank Cihon; Lisa Cupit; Andrea Wagner; Dirk Laurent
Journal:  Lancet       Date:  2012-11-22       Impact factor: 79.321

View more
  3 in total

1.  Combination Immunotherapy With LIGHT and Interleukin-2 Increases CD8 Central Memory T-Cells In Vivo.

Authors:  Manuel F Fernandez; Guilin Qiao; Kiara Tulla; Bellur S Prabhakar; Ajay V Maker
Journal:  J Surg Res       Date:  2021-02-22       Impact factor: 2.417

2.  CDC42EP3 promotes colorectal cancer through regulating cell proliferation, cell apoptosis and cell migration.

Authors:  Qiang Feng; Dongkui Xu; Mingyao Zhou; Zijian Wu; Zhiyuan Wu; Zheng Wang; Jianjun Bi; Wei Pei
Journal:  Cancer Cell Int       Date:  2021-03-16       Impact factor: 5.722

3.  The effects of ARID1A mutations on colorectal cancer and associations with PD-L1 expression by stromal cells.

Authors:  Tomohiro Kamori; Eiji Oki; Yoshifumi Shimada; Qingjiang Hu; Yuichi Hisamatsu; Koji Ando; Mototsugu Shimokawa; Toshifumi Wakai; Yoshinao Oda; Masaki Mori
Journal:  Cancer Rep (Hoboken)       Date:  2021-05-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.